Dr. McKinnell has served as an independent director of ChemoCentryx, Inc. (formerly NASDAQ:CCXI) from 2016 to 2022, which was subsequently acquired by Amgen (NYSE:AMGN). Dr. McKinnell has served as an independent director of Moody’s Corporation (NYSE:MCO) from 1997 until 2012, and served as the Independent Chairman from 2012 until 2021.

Dr. McKinnell has served as an independent director of Agiliti, Inc. (NYSE:AGTI) from 2016 to 2022, an independent director of ViewRay, Inc. (NASDSAQ:VRAY) from 2016 to 2019, and an independent director of ExxonMobil Corporation (NYSE:XOM) from 2002 to 2007. Dr. McKinnell served as the Chief Executive Officer of Optimer Pharmaceuticals, Inc. (formerly NASDAQ:OPTR) in 2013, until its acquisition by Cubist Pharmaceuticals (formerly NASDAQ:CBST, now Merck & Co. NYSE:MRK). Prior, Dr. McKinnell served as Chairman of the Board and Chief Executive Officer of Pfizer Inc. (NYSE:PFE) from 2001 until his retirement in 2006. He served as President of Pfizer Inc. from 1999 to 2001, and as President of Pfizer Pharmaceuticals Group from 1997 to 2001. Dr. McKinnell served as Chief Operating Officer of Pfizer Inc. from 1999 to 2000 and as Executive Vice President from 1992 to 1999. Dr. McKinnell joined Pfizer in 1971. He served as a Director of Emmaus Life Sciences until 2015. He served as a director of Angiotech Pharmaceuticals, Inc. until 2011, and John Wiley & Sons until 2005.

Dr. McKinnell is the Chairman Emeritus of the Pharmaceutical Research and Manufacturers of America (PhRMA). He also served as a Senior Advisor to Toyota Motor Corporation’s International Advisory Board and the Thomas H. Lee Private Equity Partnership. Dr. McKinnell holds a bachelor’s degree in business from the University of British Columbia and an M.B.A. and Ph.D. from Stanford University Graduate School of Business. Dr. McKinnell brings to the Board financial expertise, global management experience and leadership skills.

Dr. McKinnell brings to the Board an appreciation of what a complex regulatory environment means for the Company’s operations. Dr. McKinnell has also served as a director of several public companies, contributing to his perspective on corporate governance matters.

Dr. Coleman is President Emerita of the University of Michigan, having served as President from 2002 to 2014, where she was named one of “10 Best College Presidents” by TIME Magazine and served as President of the University of Michigan Health System. Dr. Coleman served as an Independent Director of Johnson & Johnson (NYSE:JNJ) for over a decade from 2003 to 2016, chairing the Audit Committee, as a member of the Audit Committee and a member of the J&J Technology/Science/R&D Committee. Dr. Coleman served as an independent director of Meredith Corporation (formerly NYSE:MDP) from 1997 to 2016, as well as a director of Gaylord Container Corp. She also was a Professor of Biological Chemistry in the University of Michigan Medical School and a Professor of Chemistry in the University of Michigan College of Literature, Science and the Arts. From 1995 to July 2002, Dr. Coleman served as President of the University of Iowa. Prior to 1995, Dr. Coleman served as Provost and Vice President for Academic Affairs at the University of New Mexico, Vice Chancellor for Graduate Studies & Research and Associate Provost and Dean of Research at the University of North Carolina at Chapel Hill, and a member of the biochemistry faculty and an administrator at the Cancer Center of the University of Kentucky in Lexington. President Obama selected Dr. Coleman to help launch the Advanced Manufacturing Partnership, a national effort bringing together industry, universities and the federal government. In 2010, U.S. Commerce Secretary Gary Locke named Dr. Coleman co-chair of the National Advisory Council on Innovation and Entrepreneurship. Elected to the National Academy of Sciences’ Institute of Medicine in 1997, Dr. Coleman is a Fellow of the American Academy of Arts and Sciences and the American Association for the Advancement of Science. Dr. Coleman is a Trustee Emerita of the Gerald R. Ford Foundation, the Gates Cambridge Scholarship program, and the Mayo Clinic Foundation, and is on the Board of Directors of The Kavli Foundation.

Jeffrey H. Cooper is a former Audit Committee Chair and Independent Director for Sierra Oncology (formerly NASDAQ:SRRA) from 2016 until 2022, until it was acquired by GlaxoSmithKline (NYSE:GSK). Mr. Cooper also previously served on the Board of Directors of Tobira Therapeutics (formerly NASDSAQ:TBRA) from 2014 until it was acquired by Allergan (now AbbVie NYSE:ABBV) in 2016. Mr. Cooper has served as an independent consultant for life sciences companies since January 2014. Previously, Mr. Cooper served at KaloBios Pharmaceuticals as a senior advisor in 2013 and as the Chief Financial Officer from 2012 until 2013.

Prior, Mr. Cooper served in positions of increasing responsibility at BioMarin Pharmaceutical (NASDSAQ:BMRN), beginning as Vice President, Controller, to his most recent position as Senior Vice President and Chief Financial Officer from 2007 to 2012. Mr. Cooper has also served as Vice President of Finance at Matrix Pharmaceutical and held numerous finance-related positions within the health care and pharmaceutical industries, including Corporate Controller at Foundation Health Systems and Director of Business Analysis at Syntex Corporation. Mr. Cooper received a B.A. from the University of California, Los Angeles and an M.B.A. from Santa Clara University.

Mr. Borkowski is an experienced financial executive in the pharmaceutical industry. He served as Chairman and then Lead Independent Director, First Wave Biopharma (NASDSAQ:FWBI) 2015 to date. Prior, He served as Interim Chief Financial Officer, Executive Vice President of MiMedx Group (Nasdaq: MDGX) from 2018 until 2019.

Previously, he served as the Chief Financial Officer and Executive Vice President of Mylan N.V. (formerly MYSE:MYL) from 2002 until 2009, which was acquired by Pfizer (NYSE:PFE). Mr. Borkowski has also served as Chief Financial Officer of Amerigen Pharmaceuticals, a generic pharmaceutical company with a focus on oral, controlled release products from 2013 until 2016.

In addition, Mr. Borkowski previously held the position of Chief Financial Officer with Convatec (LON:CTEC) from 2012 until 2013, a global medical device company focused on wound care and ostomy, and Carefusion (formerly NYSE:CFN) from 2009 until 2011, a global medical device company for which he helped lead its spin-out from Cardinal Health into an independent public company. Mr. Borkowski has been the Chief Financial Officer of Aceto Corporation (Nasdaq: ACET), and has held several executive positions with Concordia International, an international specialty pharmaceutical company from 2015 until 2017.

He has also served in senior financial positions at Pharmacia and American Home Products (Wyeth). He started his career with Arthur Andersen & Co. after receiving his MBA in accounting from Rutgers University subsequent to having earned his degree in Economics and Political Science from Allegheny College. Mr. Borkowski is currently a trustee and a member of the Executive Committee of Allegheny College.